Fig. 1From: PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisPRIMIS study design. PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acidBack to article page